# Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

> **NCT05529134** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Phoenicis Therapeutics** · enrollment: 8 (estimated)

## Conditions studied

- Dystrophic Epidermolysis Bullosa

## Interventions

- **DRUG:** PTW-002 10 mg/g gel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05529134
- **Lead sponsor:** Phoenicis Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-30
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-07-31
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2023-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05529134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05529134, "Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05529134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*